Weekly Digest - 24-30 Jun 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 24-30 Jun 2023
28 Jun 2023: REQORSA (quaratusugene ozeplasmid) / extensive-stage Small Cell Lung Cancer (ES-SCLC) / Genprex: Received Fast Track Designation by the FDA
- REQORSA is immunogene therapy built on a proprietary ONCOPREX Nanoparticle delivery system, claimed to be the first systemic gene therapy delivery platform used for cancer in humans
- REQORSA consists of the TUSC2 (active ingredient) gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge
- It is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge
- Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that can restore certain defective functions arising in the cancer cell
- REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells
- REQORSA has also been shown to block mechanisms that create drug resistance
- REQORSA consists of the TUSC2 (active ingredient) gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge
- REQORSA also holds 2 other FTD with:
- AstraZeneca’s TAGRISSO (in late-stage NSCLC patients with EFGR mutations)
- Merck’s KEYTRUDA (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with KEYTRUDA
